BDBM359536 (R or S)-4-(1-(2- chloro-6-cyclopropyl- 3-fluorobenzoyl)-6- (3-fluoro-[1,3'- biazetidine]-1'- carbonyl)-4,5,6,7- tetrahydro-1H- indazol-3-yl)-3- fluorobenzoic acid::US10221142, Example 21B
SMILES: OC(=O)c1ccc(-c2nn(C(=O)c3c(Cl)c(F)ccc3C3CC3)c3CC(CCc23)C(=O)N2CC(C2)N2CC(F)C2)c(F)c1
InChI Key: InChIKey=VSWDSABDRQRPPH-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuclear receptor ROR-gamma (RORC) (Homo sapiens (Human)) | BDBM359536![]() ((R or S)-4-(1-(2- chloro-6-cyclopropyl- 3-fluorobe...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I... | US Patent US10221142 (2019) BindingDB Entry DOI: 10.7270/Q2M90BZ0 | |||||||||||
More data for this Ligand-Target Pair |